Avenue Therapeutics, Inc. (NASDAQ:ATXI – Get Free Report) traded up 3.7% on Tuesday . The stock traded as high as $0.6749 and last traded at $0.6749. 327 shares traded hands during mid-day trading, a decline of 100% from the average session volume of 119,177 shares. The stock had previously closed at $0.6506.
Avenue Therapeutics Stock Up 3.7%
The firm has a 50-day moving average price of $0.76 and a two-hundred day moving average price of $0.59. The firm has a market cap of $2.15 million, a PE ratio of 0.04 and a beta of -0.33.
About Avenue Therapeutics
Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.
Featured Articles
- Five stocks we like better than Avenue Therapeutics
- How to trade penny stocks: A step-by-step guide
- Why Taiwan Semiconductor’s 6.5% Dip Could Be a Smart Buy
- Why Invest in 5G? How to Invest in 5G Stocks
- RTX Surges to Record Highs as Defense Orders Explode
- Consumer Discretionary Stocks Explained
- Smart Money Is Buying Auto Suppliers, Not Car Brands
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
